MOVING LIFE SCIENCE INNOVATIONS

FROM DISCOVERY TO DEVELOPMENT TO DELIVERY

OUR VISION OF THE FUTURE: Arizona is a top-ten life science state.

OUR MISSION: AZBio supports the needs of Arizona’s growing life science ecosystem.

OUR MEMBERS: AZBio Members make an impact. They discover, develop and deliver health innovations including medicines, medical devices, diagnostics, and a wide range of health technologies. Our members also include economic development partners, educators, investors, leading business and philanthropic organizations, and patient advocacy organizations. AZBio Members employ over 365,000 Arizonans who are working together to make life better for people in Arizona and around the world.

Our industry sector generated over $43.64 billion in Economic Impact in 2023.

That's up over 88% from 2016 and growing at a Compound Annual Growth Rate of 9.5%.

Arizona’s bioscience industry (not including our hospitals) employed 40,399 in 2023 across 3,652 state business establishments, representing a rapid 24.6 percent increase in employment since 2019 and placing the state among the leaders in employment growth. The average wage in the bioscience industry was $102,161—53 percent higher than the state’s private sector average. View More of Arizona's Bioscience Industry Data

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on growing Arizona’s bioscience industry.

AZBio Member Organizations in the fields of business, research and education, health care delivery, economic development, government, and other professions involved in the biosciences are the key drivers of the growth of Arizona's life science sector. As the unified voice of our industry in Arizona, AZBio strives to make Arizona a place where bioscience organizations can grow and succeed.

AZBio works nationally and globally with the Advanced Medical Technology Association (AdvaMed), the Biotechnology Innovation Organization (BIO), the Medical Device Manufacturers Association (MDMA), the Pharmaceutical Research and Manufacturers of America (PhRMA), and leading patient advocacy organizations.

Through these relationships, AZBio has access to information, contacts, resources, cost saving programs, and the global bioscience and medtech community.

BIO Unveils Strategic Initiative to Speed Scientific Breakthroughs, Develop Cures and Grow the Bio-Economy

“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease and Save Lives” Provides Roadmap for Transformative Policy Changes WASHINGTON, D.C. (Wednesday, June 29, 2011) – The Biotechnology Industry Organization (BIO) released today a summary of legislative proposals to reform the investment and regulatory environment for biotech innovation. These proposals are designed to unleash […]

AZBio News – June 2011

Biosphere 2 to Have a Permanent Home With the UA New salmonella-based ‘clean vaccines’ aid the fight against infectious disease (ASUBiodesign) BIO Unveils Strategic Initiative to Speed Scientific Breakthroughs, Develop Cures and Grow the Bio-Economy (BIO) International Genomics Consortium contributes to The Cancer Genome Atlas’ detailed ovarian cancer analysis Findings point to new means of assessing patient […]

Washington Watch: the debt ceiling and deficit debate in DC

There has been a lot of talk about budgets and debt ceilings in Washington this week. The negotiations – now taking place between the President and Congressional leaders are fluid, closely held, and difficult to predict. It does not take a PhD to know that Medicare and Medicaid cuts are on the table. At AZBIO we […]

BIO Praises House Passage of Patent Reform Legislation

Press Release from BIO: The Leahy-Smith America Invents Act will benefit all sectors of U.S. economy Washington, D.C. (June 23, 2011) – Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement on the passage of The Leahy-Smith America Invents Act, H.R. 1249, by the House of Representatives:“Small biotechnology companies rely heavily […]